Regenerative Therapies and Devices

再生疗法和设备创新和知识中心将提供一个可持续的区域和国际平台，以解决再生疗法和设备中新技术的创造及其在日益增加的成本限制的复杂全球市场中加速采用的问题。促进身体组织再生的疗法和设备为医疗保健带来了革命性变化，并成为经济增长的催化剂，在医疗保健技术领域创造了一个新的商业部门(Foresight Healthcare 2020)。该中心专注于生物支架、纳米生物材料和自组装肽方面的新兴新技术。这些混合技术利用新的物理和生物功能，通过利用体内内源干细胞的潜力来增强和加速组织的再生。这些新技术还将为未来将外源干细胞输送给患者提供一种载体，并可用于体外生成新组织。通过改进诊断和成像以增强患者目标，以及通过新的复杂模拟方法(实验室中的患者)改进对长期临床结果的短期预测，这些新兴技术将加快向患者交付。由于生物医学和保健的进步，人口的预期寿命和平均年龄继续增加，这造成了额外的社会和经济负担。再生技术和设备IKC将满足老龄化人口的生活需求和质量，并满足他们对50岁后50年后再过50年的积极生活方式的期望。它将特别但不只是专注于肌肉骨骼疾病、牙科、心血管疾病和癌症等临床需求领域，这些领域一直是该大学和利兹医院信托基金的战略优先事项。该中心将建立和发展大量的临床、学术和行业伙伴关系。超过5800万美元的额外新合作资金已经得到确认，以匹配IKC奖，该中心已制定计划，在其活动的最初五年期间，在该领域的研究和创新资金超过1亿美元。这一快速增长的多学科领域将需要创新的科学家和工程师，他们能够跨越学科边界，在更广泛的基于系统的项目中工作，并在创新管道的不同阶段与行业和临床医生灵活协作。该中心及其合作伙伴将在创新周期的早期阶段开发新的和不同的创新方法，以大幅加快创新，缩短临床试验和上市的时间，并降低与这一新兴领域相关的技术风险。利兹大学商学院的合作者将开发和评估开放式创新方法。利兹大学是利用这一EPSRC号召的理想选择，原因有四个。首先，它在技术和科学方面拥有相当大的能力，以及管理协作创新和创业的能力。其次，它有能力管理、促进和创造新兴医疗技术的加速创新。第三，该大学已经拥有一流的设施和创新记录(WRHIP)，并正在与约克郡前进合作，建立一个医疗保健技术创新中心。第四，与临床试验研究单位和卫生经济单位的战略伙伴关系将使其能够过渡到国民保健制度的实践。

The Innovation and Knowledge Centre in Regenerative Therapies and Devices will provide a sustainable regional and international platform to address the creation of new technologies in Regenerative Therapies and Devices and their accelerated adoption within a complex global market place with increasing cost constraints. Therapies and devices which facilitate the regeneration of body tissues offer the potential to revolutionise healthcare and be a catalyst for economic growth, creating a new business sector within healthcare technology (Foresight Healthcare 2020). This centre is focused on emerging novel technologies in biological scaffolds, nano-biomaterials and self assembling peptides. These hybrid technologies utilise novel physical and biological functionality to enhance and accelerate the regeneration of tissues by harnessing the potential of endogenous stem cells in vivo. These novel technologies will also provide a vehicle for the delivery of exogenous stem cells to patients in the future and can be used to generate neo-tissues in vitro. The delivery of these emerging technologies to patients will be accelerated by improved diagnostics and imaging for enhanced patient targeting and by new complex simulation methodologies (patient in the lab) for improved short term predictions of the long term clinical outcomes. The life expectancy and average age of the population continues to increase as a result of advances in biomedicine and healthcare and this is generating additional social and economic burden. The Regenerative Technologies and Devices IKC will address the needs and quality of life of the ageing population, and address their expectations of an active lifestyle for fifty more years after fifty . It will specifically, but not exclusively, focus on areas of clinical need in musculoskeletal disease, dentistry, cardiovascular disease and cancer, which have been strategically prioritised by the University and the Leeds Hospitals Trust. The centre will build upon and develop substantial clinical, academic and industry partnerships. Additional new collaborative funding of over 58 million has already been confirmed to match the IKC award, and the centre has plans which have identified research and innovation funding in this area of over 100 million during the initial five year period of its activities.This rapidly growing multidisciplinary area will require innovative scientists and engineers who can cross disciplinary boundaries, work in broader systems based projects and work flexibly and collaboratively with industry and clinicians at different stages of the innovation pipeline. The centre and its partners will develop new and different approaches to innovation at an early stage of the innovation cycle, to substantially accelerate innovation, shorten the time period to clinical trials and market, and mitigate technology risks associated with this emergent sector. Collaborators in the Leeds University Business School will develop and evaluate open innovation methodologies. The University of Leeds is ideally placed to take advantage of this EPSRC call for four important reasons. First it has considerable competency in technology and science, as well as capabilities in managing collaborative innovation and entrepreneurship. Second it has the capability to both manage facilitate and create accelerated innovation in emerging healthcare technologies. Third the University already has excellent facilities and a track record (WRHIP) for innovation and is working with Yorkshire Forward to establish an Innovation Hub in Healthcare Technologies. Fourth the strategic partnership with the Clinical Trials Research Unit and the Unit of Health Economics will enable transition into NHS practice.